Dr Reddys Laboratories (RDY) EBITDA (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly EBITDA of $215.0 million for Q2 2023, down 17.31% quarter-over-quarter from $260.0 million in Q1 2023.

Dr Reddys Laboratories (RDY) EBITDA (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' EBITDA history runs 15 years deep, the most recent figure standing at $215.0 million for Q2 2023.

In Q2 2023, EBITDA changed N/A year-over-year to $215.0 million; the TTM figure through Jun 2023 stood at $200000.7 billion (changed N/A YoY), while the FY2026 annual figure was $539.0 million, down 35.99% from the prior year.
EBITDA for Q2 2023 stood at $215.0 million, down from $260.0 million in the prior quarter.
The five-year high for EBITDA was $200000.0 billion in Q3 2022, with the low at -$82.0 million in Q3 2019.
The 5-year median for EBITDA is $113.0 million (2019), against an average of $16666.8 billion.
Peak annual rise in EBITDA reached 69.7% in 2019, while the deepest fall reached 198.8% in 2019.
Dr Reddys Laboratories' EBITDA stood at -$82.0 million in 2019, then increased by 2.44% to -$80.0 million in 2020, then surged by 303.75% to $163.0 million in 2021, then gained by 22.09% to $199.0 million in 2022, then grew by 8.04% to $215.0 million in 2023.
Business Quant data shows RDY's EBITDA at $215.0 million in Q2 2023, $260.0 million in Q1 2023, and $199.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-231.00 Mn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	837.00 Mn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	1.26 Bn
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	330.80 Mn
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	6.30 Mn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	151.50 Mn
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	248.00 Mn
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	18.35 Mn

Download Data